Literature DB >> 20466882

MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis.

S Hani Najafi-Shoushtari1, Fjoralba Kristo, Yingxia Li, Toshi Shioda, David E Cohen, Robert E Gerszten, Anders M Näär.   

Abstract

Proper coordination of cholesterol biosynthesis and trafficking is essential to human health. The sterol regulatory element-binding proteins (SREBPs) are key transcription regulators of genes involved in cholesterol biosynthesis and uptake. We show here that microRNAs (miR-33a/b) embedded within introns of the SREBP genes target the adenosine triphosphate-binding cassette transporter A1 (ABCA1), an important regulator of high-density lipoprotein (HDL) synthesis and reverse cholesterol transport, for posttranscriptional repression. Antisense inhibition of miR-33 in mouse and human cell lines causes up-regulation of ABCA1 expression and increased cholesterol efflux, and injection of mice on a western-type diet with locked nucleic acid-antisense oligonucleotides results in elevated plasma HDL. Our findings indicate that miR-33 acts in concert with the SREBP host genes to control cholesterol homeostasis and suggest that miR-33 may represent a therapeutic target for ameliorating cardiometabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466882      PMCID: PMC3840500          DOI: 10.1126/science.1189123

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been.

Authors:  Timothy F Osborne; Peter J Espenshade
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

Review 3.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Authors:  Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-14       Impact factor: 8.311

Review 5.  MicroRNA control of muscle development and disease.

Authors:  Andrew H Williams; Ning Liu; Eva van Rooij; Eric N Olson
Journal:  Curr Opin Cell Biol       Date:  2009-03-09       Impact factor: 8.382

6.  Increased ABCA1 activity protects against atherosclerosis.

Authors:  Roshni R Singaraja; Catherine Fievet; Graciela Castro; Erick R James; Nathalie Hennuyer; Susanne M Clee; Nagat Bissada; Jonathan C Choy; Jean-Charles Fruchart; Bruce M McManus; Bart Staels; Michael R Hayden
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 7.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Authors:  Alan R Tall; Laurent Yvan-Charvet; Naoki Terasaka; Tamara Pagler; Nan Wang
Journal:  Cell Metab       Date:  2008-05       Impact factor: 27.287

Review 8.  Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL.

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  J Lipid Res       Date:  2008-10-29       Impact factor: 5.922

9.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.

Authors:  Daniel J Rader; Eric T Alexander; Ginny L Weibel; Jeffrey Billheimer; George H Rothblat
Journal:  J Lipid Res       Date:  2008-12-08       Impact factor: 5.922

Review 10.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

View more
  421 in total

Review 1.  Post-transcriptional regulation in metabolic diseases.

Authors:  Wook Kim; Eun Kyung Lee
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Authors:  F Cerrato; M E Fernández-Suárez; R Alonso; M Alonso; C Vázquez; O Pastor; P Mata; M A Lasunción; D Gómez-Coronado
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

Review 3.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

4.  Cardiovascular disorders: MicroRNA modulation of cholesterol.

Authors:  Charlotte Harrison
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 5.  miRNAs: roles and clinical applications in vascular disease.

Authors:  Md Saha Jamaluddin; Sarah M Weakley; Lidong Zhang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

Review 6.  MicroRNAs in metabolic disease.

Authors:  Carlos Fernández-Hernando; Cristina M Ramírez; Leigh Goedeke; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

Review 7.  Chromatin and beyond: the multitasking roles for SIRT6.

Authors:  Sita Kugel; Raul Mostoslavsky
Journal:  Trends Biochem Sci       Date:  2014-01-14       Impact factor: 13.807

Review 8.  Regulation of SIRT1 by microRNAs.

Authors:  Sung-E Choi; Jongsook Kim Kemper
Journal:  Mol Cells       Date:  2013-11-06       Impact factor: 5.034

Review 9.  Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism.

Authors:  Ángel Baldán; Carlos Fernández-Hernando
Journal:  Curr Opin Lipidol       Date:  2016-12       Impact factor: 4.776

10.  MicroRNA-33a promotes cell proliferation and inhibits apoptosis by targeting PPARα in human hepatocellular carcinoma.

Authors:  Weiping Chang; Lei Zhang; Yao Xian; Zhaoxiang Yu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.